(R)-9-(2-Hidroksipropil)Adenin CAS NO.14047-28-0

Temel Bilgiler

Kimyasal özellikler

Kullanım ve Sentez

The final product of this substance was administered with tenofovir disoproxil fumarate at the same time, and the maximum serum concentration (Cmax) and the area under the plasma concentration-time curve (AUC) of the sustained-release creatinine tablets or enteric-coated preparations increased significantly. high. The mechanism of this interaction is unclear. Higher levels of creatinine may cause adverse events related to creatinine, including pancreatitis and kidney disease. Decreased CD4 cell counts were observed in patients receiving tenofovir disoproxil fumarate and 400 mg of didano-creatinine daily. In adults with a body weight of >60 kg'lık hastalarda, tenofovir disoproksil fumarat ile birlikte kullanıldığında dehidroksikreatinin dozu 250 mg'a düşürülmelidir. Vücut ağırlığı 60 kg olan hastalarda, tenofovir disoproksil fumarat ile birlikte kullanıldığında dehidroksikreatinin dozu 250 mg'a düşürülmelidir.<60 kg, there is no data on the recommended dose adjustment of creatinine. For combined administration, tenofovir disoproxil fumarate and deshydroxycreatinine enteric solvent can be taken on an empty stomach or after eating light food. Dehydroxycreatinine sustained-release tablets and tenofovir disoproxil fumarate should be administered in combination on an empty stomach. Tenofovir disoproxil fumarate should be used with caution when combined with deshydroxycreatinine, and patients receiving the combination should be closely monitored for adverse events related to deshydroxycreatinine. Dehydroxycreatinine should be discontinued in patients with adverse events related to deshydroxycreatinine